Free Trial
NASDAQ:INDP

Indaptus Therapeutics (INDP) Stock Price, News & Analysis

Indaptus Therapeutics logo
$0.88 +0.04 (+4.75%)
As of 03:59 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

About Indaptus Therapeutics Stock (NASDAQ:INDP)

Key Stats

Today's Range
$0.85
$0.88
50-Day Range
$0.84
$1.18
52-Week Range
$0.81
$3.10
Volume
10,369 shs
Average Volume
22,814 shs
Market Capitalization
$9.00 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$8.50
Consensus Rating
Buy

Company Overview

Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, and chronic hepatitis B virus, and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.

Indaptus Therapeutics Stock Analysis - MarketRank™

See Top Rated MarketRank™ Stocks
65th Percentile Overall Score

INDP MarketRank™: 

Indaptus Therapeutics scored higher than 65% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Indaptus Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 2 buy ratings, no hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Indaptus Therapeutics has only been the subject of 1 research reports in the past 90 days.

  • Read more about Indaptus Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Indaptus Therapeutics are expected to grow in the coming year, from ($1.79) to ($1.38) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Indaptus Therapeutics is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Indaptus Therapeutics is -0.52, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Indaptus Therapeutics has a P/B Ratio of 0.61. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Indaptus Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    0.81% of the float of Indaptus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Indaptus Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Indaptus Therapeutics has recently decreased by 19.14%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Indaptus Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Indaptus Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    0.81% of the float of Indaptus Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Indaptus Therapeutics has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Indaptus Therapeutics has recently decreased by 19.14%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Indaptus Therapeutics this week, compared to 0 articles on an average week.
  • Search Interest

    1 people have searched for INDP on MarketBeat in the last 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Indaptus Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    29.50% of the stock of Indaptus Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 7.06% of the stock of Indaptus Therapeutics is held by institutions.

  • Read more about Indaptus Therapeutics' insider trading history.
Receive INDP Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Indaptus Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

INDP Stock News Headlines

Indaptus Therapeutics Announces $2.25 Million Private Placement
I was wrong. Dead wrong.
I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we are, a quarter of a century later, almost to the exact day, and it’s happening again.
Indaptus Therapeutics announces anticipated milestones in 1H of 2025
See More Headlines

INDP Stock Analysis - Frequently Asked Questions

Indaptus Therapeutics' stock was trading at $0.8421 at the beginning of the year. Since then, INDP shares have increased by 4.7% and is now trading at $0.8820.
View the best growth stocks for 2025 here
.

Indaptus Therapeutics, Inc. (NASDAQ:INDP) issued its earnings results on Tuesday, November, 12th. The company reported ($0.32) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.47) by $0.15.

Shares of INDP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Indaptus Therapeutics investors own include NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), General Electric (GE), Meta Platforms (META), Adobe (ADBE) and CrowdStrike (CRWD).

Company Calendar

Last Earnings
11/12/2024
Today
1/21/2025
Next Earnings (Estimated)
3/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:INDP
Employees
6
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$8.50
High Stock Price Target
$12.00
Low Stock Price Target
$5.00
Potential Upside/Downside
+870.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-15,420,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$1.44 per share

Miscellaneous

Free Float
7,189,000
Market Cap
$8.94 million
Optionable
Not Optionable
Beta
1.47
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

This page (NASDAQ:INDP) was last updated on 1/21/2025 by MarketBeat.com Staff
From Our Partners